Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...